A unique research and production complex organized on the principle of full integration.
The Company has all the competencies required to develop and manufacture original and generic medicines to treat cancer and other high-profile diseases.
Since 2020, the Company has been based at Technopolis Moscow SEZ.
High level of social responsibility
Innovative technological solutions
Adherence to high ethical principles
and r&d center
Manufacturing processes use effective, state-of-the-art equipment from leading foreign companies.
To date, 140 units of high-tech machines of world brands have been purchased, which makes it possible to consolidate efforts in the development, manufacture and quality control of medicines of various dosage forms.
10 millionpacks per year of solid dosage forms
6 millionpacks per year of sterile dosage forms
100 kgper year of small-volume manufacture of apis for own manufacturing needs
Own R&D Center develops original, generic and hybrid drugs based on small molecules of chemical
We have created a state-of-the-art research and manufacturing platform for the development and manufacture of our own active pharmaceutical ingredients and finished pharmaceutical products based on them.
According to the World Health Organization, cancer is one of the leading causes of morbidity and
Oncological diseases are systemic and affect all human organs and systems in one way or another.
550,000new cases of oncological diseases were registered in russia in 2020
High mortality rates from cancer can be reduced if the following conditions are met:
USE OF EFFECTIVE MEDICINES
Targeted therapy – a type of drug therapy used to treat oncological diseases, has a targeted effect on intracellular mechanisms that affect tumor growth.
Targeted treatment compares favorably with classical chemotherapy in that it "forces" the patient's
own immune system to selectively attack only cancer cells, causing little or no damage to healthy
cells and body tissues.
Development and registration of antitumor drugs is an urgent task both for the healthcare system as a whole and specifically for the Russian full-cycle pharmaceutical company OncoTarget.
86% of the product portfolio is included in the list of Vital and Essential Drugs.
Oncology / Oncohematology
HIV and infectious diseases
more than 18
molecules to treat oncological diseases will appear in the company's portfolio
more than 16 million
packs of drugs will be produced
medicinal products are planned for release
OncoTarget manufacturing is in full compliance with international pharmacological industry quality standards.